Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyANG Lifesciences India Ltd 2CIN NO.L24230PB2006PLC030341 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Harshita Aggarwal Designation: Company Secretary EmailId: cs@anglifesciences.com Name of the Chief Financial Officer: Saruchi Gupta Designation: CFO EmailId: saruchigupta1977@gmail.com Date: 24/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

ANG Lifesciences India Ltd.

22 Apr 2025

28.75

4.66%

Company Update

ANG Lifesciences India Ltd - 540694 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Compliance certificate under Reg 74(5) of SEBI (DP) Regulations, for quarter ended 31.03.2025.

pdf

ANG Lifesciences India Ltd.

01 Apr 2025

28.75

4.66%

SAST

ANG Lifesciences India Ltd - 540694 - Closure of Trading Window

BSE India

Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with Company''s Code of Conduct to regulate, monitor and report the trading of equity shares. The trading window for dealing in the securities of company shall remain closed from 1st April, 2025 for the insider, designated persons and their immediate relatives till the end of 48 hours after declaration of Results for the quarter ending 31st, March 2025.

pdf

ANG Lifesciences India Ltd.

20 Mar 2025

28.75

4.66%

Company Update

ANG Lifesciences India Ltd - 540694 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - …

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that Mr. Karun Singh, Group Opertaions Head of the Company had a Zoom meet with Mr. Milin Ramani on 20-MArch-2025.

pdf

ANG Lifesciences India Ltd.

12 Mar 2025

28.75

4.66%

Company Update

ANG Lifesciences India Ltd - 540694 - Appointment of Company Secretary and Compliance Officer

BSE India

Pursuant to Regulation 30 of SEBI (LODR), Regulations 2015, the Board of Directors at the meeting held on today March 12, 2025 have considered and appointed Ms. Harshita Aggarwal as the Company Secretary and Compliance Officer of the company w.e.f March 12, 2025.

pdf

ANG Lifesciences India Ltd.

15 Feb 2025

28.75

4.66%

Company Update

ANG Lifesciences India Ltd - 540694 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Enclosed are the newspaper publication of Unaudited Financial Results 31.12.2024.

pdf

ANG Lifesciences India Ltd.

14 Feb 2025

28.75

4.66%

Corp. Note

ANG Lifesciences India Ltd - 540694 - Integrated Filing (Financial)

BSE India

Integrated Filling (Financials)

pdf

ANG Lifesciences India Ltd.

14 Feb 2025

28.75

4.66%

Result

ANG Lifesciences India Ltd - 540694 - UNAUDITED FINANCIAL RESULTS FOR Q.E. 31-12-2024

BSE India

Unaudited Financial Results for Quarter and nine months ended 31.12.2024.

pdf

ANG Lifesciences India Ltd.

14 Feb 2025

28.75

4.66%

Board Meeting

ANG Lifesciences India Ltd - 540694 - Board Meeting Outcome for Board Meeting Outcome For SUBMISSION …

BSE India

Pursuant to Regulation 30 & 33 read with clause 4 (h) of Para A of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulation, 2015 (''Listing Regulations''), this is to inform your that Board of Directors in its meeting held today i.e., February 14, 2025, have inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024, along with Limited Review Report issued by Statutory Auditors of the Company. A copy of the same is enclosed herewith.

pdf

Is ANG Lifesciences India Ltd. worth buying?

61 Votes:

Buy 77.05%

Sell 11.48%

Hold 11.48%

54.18% Fall from 52W High

High volume today

ANG Lifesciences India Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from ANG Lifesciences India Ltd. on BSE